Back to today’s briefing

Story perspectives

New Obesity Drug Achieves 19.9% Weight Loss in Trials

7/3/2025

25 3

Summary

Story summary

In a groundbreaking phase 2 trial with 592 participants, the new obesity medication Maridebart cafraglutide achieved an impressive weight loss of up to 19.9%. This innovative drug uniquely combines GLP-1 receptor agonism and GIP receptor antagonism, boasting a longer half-life than current options. Meanwhile, semaglutide emerges as a promising ally in managing type 1 diabetes, enhancing blood sugar control while aiding weight loss.

1 of 1

Story summary

In a groundbreaking phase 2 trial with 592 participants, the new obesity medication Maridebart cafraglutide achieved an impressive weight loss of up to 19.9%. This innovative drug uniquely combines GLP-1 receptor agonism and GIP receptor antagonism, boasting a longer half-life than current options. Meanwhile, semaglutide emerges as a promising ally in managing type 1 diabetes, enhancing blood sugar control while aiding weight loss.